Tissue Repair Past Earnings Performance
Past criteria checks 0/6
Tissue Repair's earnings have been declining at an average annual rate of -12.6%, while the Biotechs industry saw earnings growing at 12.6% annually. Revenues have been growing at an average rate of 87.2% per year.
Key information
-12.6%
Earnings growth rate
13.9%
EPS growth rate
| Biotechs Industry Growth | 9.6% |
| Revenue growth rate | 87.2% |
| Return on equity | -22.9% |
| Net Margin | -231.1% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Tissue Repair makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 2 | -4 | 3 | 3 |
| 31 Mar 24 | 1 | -4 | 3 | 3 |
| 31 Dec 23 | 1 | -3 | 3 | 2 |
| 30 Sep 23 | 1 | -4 | 3 | 2 |
| 30 Jun 23 | 1 | -4 | 3 | 3 |
| 31 Mar 23 | 1 | -5 | 3 | 3 |
| 31 Dec 22 | 0 | -5 | 3 | 3 |
| 30 Sep 22 | 0 | -6 | 3 | 2 |
| 30 Jun 22 | 0 | -7 | 3 | 1 |
| 31 Mar 22 | 0 | -6 | 2 | 1 |
| 31 Dec 21 | 0 | -6 | 2 | 1 |
| 30 Sep 21 | 0 | -3 | 1 | 0 |
| 30 Jun 21 | 0 | -1 | 0 | 0 |
| 30 Jun 20 | 0 | 0 | 0 | 0 |
Quality Earnings: TRP is currently unprofitable.
Growing Profit Margin: TRP is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: TRP is unprofitable, and losses have increased over the past 5 years at a rate of 12.6% per year.
Accelerating Growth: Unable to compare TRP's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: TRP is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (2.6%).
Return on Equity
High ROE: TRP has a negative Return on Equity (-22.94%), as it is currently unprofitable.